---
title: "Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Safety questions"
description: "Safety questions on Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Monitoring, Safety management, and Safety and prevention. Questions: After a DATROWAY infusion, how long should patients be monitored? What are the most common DATROWAY side effects in HR-positive, HER2-negative breast cancer? How often did DATROWAY cause serious side effects in TROPION-Breast01? DATROWAY vs chemotherapy: how common were Grade 3 or higher side effects (TROPION-Breast01)? 6 further questions follow. 10 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer: Safety questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Datroway](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Datroway&inline=true)

## Monitoring

<a id="datroway-infusion-monitoring"></a>

### After a DATROWAY infusion, how long should patients be monitored?

> “Monitor patients for infusion-related reactions in a setting where cardiopulmonary resuscitation medication and equipment are available<sup>1</sup>
> Monitor patients for at least 1 hour for the first 2 cycles of DATROWAY infusions. If there are no infusion-related reactions observed, monitor patients for at least 30 minutes for all subsequent cycles of infusions<sup>1</sup>”

Source: [DATROWAY: Dosing & Administration, captured 2026-11-08](https://datrowayhcp.com/dosing-administration#:~:text=Monitor%20patients%20for%20infusion%2Drelated%20reactions,for%20all%20subsequent%20cycles%20of)

## Safety

<a id="datroway-common-adverse-reactions"></a>

### What are the most common DATROWAY side effects in HR-positive, HER2-negative breast cancer?

> “The safety of DATROWAY was evaluated in 360 patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC1+ or IHC2+/ISH-) breast cancer who received at least one dose of DATROWAY 6 mg/kg in TROPION-Breast01. DATROWAY was administered by intravenous infusion once every three weeks. The median duration of treatment was 6.7 months (range: 0.7 months to 16.1 months) for patients who received DATROWAY.”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=TROPION%2DBreast01-,The%20safety%20of%20DATROWAY%20was%20evaluated%20in%20360%20patients%20with,for%20patients%20who%20received%20DATROWAY.)

> “The most common (≥20%) adverse reactions, including laboratory abnormalities, were stomatitis (59%), nausea (56%), fatigue (44%), decreased leukocytes (41%), decreased calcium (39%), alopecia (38%), decreased lymphocytes (36%), decreased hemoglobin (35%), constipation (34%), decreased neutrophils (30%), dry eye (27%), vomiting (24%), increased ALT (24%), keratitis (24%), increased AST (23%), and increased alkaline phosphatase (23%).”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=The%20most%20common%20%28%E2%89%A520%25%29%20adverse%20reactions%2C,and%20increased%20alkaline%20phosphatase%20%2823%25%29.)

<a id="datroway-serious-adverse-reactions"></a>

### How often did DATROWAY cause serious side effects in TROPION-Breast01?

> “Serious adverse reactions occurred in 15% of patients who received DATROWAY. Serious adverse reactions in >0.5% of patients who received DATROWAY were urinary tract infection (1.9%), COVID-19 infection (1.7%), ILD/pneumonitis (1.1%), acute kidney injury, pulmonary embolism, vomiting, diarrhea, hemiparesis, and anemia (0.6% each). Fatal adverse reactions occurred in 0.3% of patients who received DATROWAY and were due to ILD/pneumonitis.
>
> Permanent discontinuation of DATROWAY due to an adverse reaction occurred in 3.1% of patients. Adverse reactions which resulted in permanent discontinuation of DATROWAY in >0.5% of patients included ILD/pneumonitis (1.7%) and fatigue (0.6%).
>
> Dosage interruptions of DATROWAY due to an adverse reaction occurred in 22% of patients. Adverse reactions which required dosage interruption in >1% of patients included COVID-19 (3.3%), infusion-related reaction (1.4%), ILD/pneumonitis (1.9%), stomatitis (1.9%), fatigue (1.7%), keratitis (1.4%), acute kidney injury (1.1%), and pneumonia (1.1%).
>
> Dose reductions of DATROWAY due to an adverse reaction occurred in 23% of patients. Adverse reactions which required dose reduction in >1% of patients included stomatitis (13%), fatigue (3.1%), nausea (2.5%), and weight decrease (1.9%).”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=Serious%20adverse%20reactions%20occurred%20in,%282.5%25%29%2C%20and%20weight%20decrease%20%281.9%25%29.)

<a id="datroway-grade3-vs-chemotherapy"></a>

### DATROWAY vs chemotherapy: how common were Grade 3 or higher side effects (TROPION-Breast01)?

> “Grade ≥3 TRAEs were 21% with DATROWAY (n=360) and 45% with chemotherapy (n=351)<sup>2</sup>”

Source: [DATROWAY: DATROWAY® (datopotamab deruxtecan-dlnk) | HR+/HER2– mBC, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc#:~:text=Grade%20%E2%89%A53%20TRAEs%20were%2021%25%20with%20DATROWAY%20%28n%3D360%29%20and%2045%25%20with%20chemotherapy)

> “TRAEs refer to adverse events possibly related to treatment as assessed by the investigator. Adverse reactions refer to adverse events which have a likely basis for a causal relationship between the drug and the occurrence of the adverse event.<sup>2,3</sup>”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=TRAEs%20refer%20to%20adverse%20events,the%20occurrence%20of%20the%20adverse)

<a id="datroway-ild-pneumonitis"></a>

### Can DATROWAY cause interstitial lung disease (ILD) or pneumonitis?

> “DATROWAY can cause severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis.
>
> Unresectable or Metastatic Breast Cancer
>
> In the pooled safety population of 841 patients with breast cancer from TROPION-Breast01, TROPION-Breast02, TROPION-PanTumor01 and TROPION-PanTumor02, ILD/pneumonitis occurred in 3.0% of patients treated with DATROWAY, including 0.4% of patients with Grade 3. There were two fatal cases (0.2%). The median time to first onset for ILD was 5.3 months (range: 1.1 months to 19.3 months) and with a median duration of 1.2 months (range: 0.3 months to 5.2 months). Eight patients (1.0%) had DATROWAY withheld and 10 patients (1.2%) permanently discontinued DATROWAY due to ILD/pneumonitis. Systemic corticosteroids were required in 64% (16/25) of patients with ILD/pneumonitis. ILD/pneumonitis resolved in 40% of patients.
>
> Patients were excluded from clinical studies for a history of ILD/pneumonitis requiring treatment with steroids or for ongoing ILD/pneumonitis.”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=Interstitial%20Lung%20Disease%2FPneumonitis-,DATROWAY%20can%20cause%20severe%2C%20life%2Dthreatening%2C%20or%20fatal%20interstitial%20lung%20disease,steroids%20or%20for%20ongoing%20ILD%2Fpneumonitis.)

<a id="datroway-eye-side-effects"></a>

### What eye side effects can DATROWAY cause?

> “DATROWAY can cause ocular adverse reactions including dry eye, keratitis, blepharitis, meibomian gland dysfunction, increased lacrimation, conjunctivitis, and blurred vision.
>
> In patients with unresectable or metastatic breast cancer and other solid tumors, ocular adverse reactions occurred in 38% of patients treated with DATROWAY. Forty-two patients (3.1%) experienced Grade 3 ocular adverse reactions, which included keratitis and dry eye, and four patients (0.3%) experienced a Grade 4 ocular adverse reaction of keratitis, corneal epithelium defect, corneal lesion, and conjunctival hemorrhage. The most common (≥5%) ocular adverse reactions were dry eye (18%), keratitis (16%), increased lacrimation (6%), and conjunctivitis (5%). The median time to first onset for ocular adverse reactions was 2.3 months (range: 0.03 months to 30 months) and with a median duration of 2.3 months (range: 0.03 months to 19.5 months). Of the patients who experienced ocular adverse reactions, 39% had complete resolution, and 8% had partial improvement (defined as a decrease in severity by one or more grades from the worst grade at last follow up). Ocular adverse reactions led to dosage interruption in 4.3% of patients, dosage reductions in 2.8% of patients, and permanent discontinuation of DATROWAY in 0.9% of patients.
>
> Patients with clinically significant corneal disease were excluded from clinical studies.”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=DATROWAY%20can%20cause%20ocular%20adverse,were%20excluded%20from%20clinical%20studies.)

<a id="datroway-stomatitis-incidence"></a>

### How common are DATROWAY mouth sores (stomatitis)?

> “DATROWAY can cause stomatitis, including mouth ulcers and oral mucositis.
>
> In patients with unresectable or metastatic breast cancer and other solid tumors, stomatitis occurred in 63% of patients treated with DATROWAY, including 8% of patients with Grade 3 events and one patient with a Grade 4 reaction. The median time to first onset of stomatitis was 0.5 months (range: 0.03 months to 19.8 months) and with a median duration of 1.1 months (range: 0.03 months to 33.2 months). Stomatitis led to dosage interruption in 5% of patients, dosage reductions in 11% of patients, and permanent discontinuation of DATROWAY in 0.4% of patients.”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=DATROWAY%20can%20cause%20stomatitis%2C%20including%20mouth%20ulcers%20and%20oral%20mucositis.,DATROWAY%20in%200.4%25%20of%20patients.)

## Safety management

<a id="datroway-ild-management"></a>

### How is DATROWAY ILD or pneumonitis managed?

> “Monitor patients for new or worsening respiratory symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever) during treatment with DATROWAY. For asymptomatic (Grade 1) ILD/pneumonitis, consider corticosteroid treatment (e.g., ≥0.5 mg/kg/day prednisolone or equivalent). For symptomatic ILD/pneumonitis (Grade 2 or greater), promptly initiate systemic corticosteroid treatment (e.g., ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks.
>
> Withhold DATROWAY in patients with suspected ILD/pneumonitis and permanently discontinue DATROWAY if ≥Grade 2 ILD/pneumonitis is confirmed.”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=Monitor%20patients%20for%20new%20or,%E2%89%A5Grade%202%20ILD%2Fpneumonitis%20is%20confirmed.)

## Safety and prevention

<a id="datroway-ocular-care"></a>

### Does DATROWAY require eye exams and eye drops?

> “Advise patients to use preservative-free lubricant eye drops at least four times daily and as needed for prophylaxis. Advise patients to avoid use of contact lenses unless directed by an eye care professional.
>
> Refer patients to an eye care professional for an ophthalmic exam including visual acuity testing, slit lamp examination (with fluorescein staining), intraocular pressure, and fundoscopy at treatment initiation, at end of treatment, and as clinically indicated. While on treatment, conduct visual acuity testing and slit lamp examination every 3 cycles.
>
> Promptly refer patients to an eye care professional for any new or worsening ocular adverse reactions. Monitor patients for ocular adverse reactions during treatment with DATROWAY, and if diagnosis is confirmed, withhold, reduce the dose, or permanently discontinue DATROWAY based on severity.”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=Advise%20patients%20to%20use%20preservative%2Dfree,discontinue%20DATROWAY%20based%20on%20severity.)

<a id="datroway-stomatitis-prevention"></a>

### How are DATROWAY mouth sores (stomatitis) prevented and managed?

> “Advise patients to use a steroid-containing mouthwash for prophylaxis and treatment of stomatitis. Instruct the patient to hold ice chips or ice water in the mouth throughout the infusion of DATROWAY.
>
> Monitor patients for signs and symptoms of stomatitis. If stomatitis occurs, increase the frequency of mouthwash and administer other topical treatments as clinically indicated. Based on the severity of the adverse reaction, withhold, reduce the dose, or permanently discontinue DATROWAY.”

Source: [DATROWAY: Safety Data from TROPION-Breast01, captured 2026-11-08](https://datrowayhcp.com/hr-positive-her2-negative-mbc/safety#:~:text=Advise%20patients%20to%20use%20a,dose%2C%20or%20permanently%20discontinue%20DATROWAY.)

## Related pages
- [Medical information: Datroway (datopotamab deruxtecan-dlnk): HR-positive HER2-negative breast cancer](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/datroway--hr-positive-her2-negative-breast-cancer/access-and-coverage)
